Low long-term adherence to weight loss drugs

Original Article by Chad Terhune | Reuters | 10 July 2024

Only 25% of US patients prescribed Wegovy or Ozempic for weight loss continued usage after two years, raising concerns about long-term adherence.

Only 25% of US patients prescribed Wegovy or Ozempic for weight loss continued usage after two years, raising concerns about long-term adherence.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Older Adults With HIV Set To Double By 2040

Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.

Read more...

Rosebank Health Village Expands Growthpoint Portfolio

Rosebank Health Village, a R100 million Growthpoint and Epione development, brings specialists, diagnostics and day surgery together.

Read more...

Global HIV Funding Cuts Put AIDS Progress At Risk

Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.

Read more...